Posts tagged “UNC-CH”
Michael Jacobs, a business executive and professor at UNC's Kenan-Flagler School of Business who also is a former U.S. Treasury official, recently taught finance in Beijing. And he returned to his North Carolina home surprised by many things he discovered. His students want to live in the U.S. "for better jobs, clean air and Facebook." And non-Chinese businesses face multiple barriers. In the third of a three-part series about building business bridges to China, Jacobs talks with WRALTechWire's Grace Ueng.
RTI partners on epilepsy work; SAS ranked in report; lawyers use cloud tools; Kenan-Flagler dean recommended; Abbott gets new trial
In our Bulldog Blog's latest life sciences and technology update: RTI partners on epilepsy network; SAS makes ranking; lawyers use more cloud tools; Kenan-Flagler dean recommended; AbbVie gets new drug trial.
President Obama's announcement to invest $70 million in federal dollars in research through a consortium of universities and private sector firms led by NCSU delivered a jolt of good news to the Triangle's fast-growing cleantech industry. RTP has become a hub for greener energy research, and the head of the Research Triangle Cleanteach Cluster says the "Next Generation Power Electronics Innovation Institute" could bring more jobs as well as investment to the region.
Researchers at UNC-Chapel Hill say they have found a way to turn solar power into a 24-hour-a-day power source by using the sun's energy to separate water molecules and create hydrogen fuel. In making the breakthrough, they received a powerful boost from scientists at N.C. State.
Chapel Hill development-stage pharmaceutical company NeuroGate Therapeutics, a spinout from the University of North Carolina at Chapel Hill, has been awarded a $25,000 grant from the Epilepsy Foundation to help the company develop its unique treatment for the debilitating condition.
If the war on cancer is won - finally - someday, a team of scientists and students in the joint biomedical engineering program at N.C. State and UNC-Chapel Hill could be a significant reason. But their technology approach is different than the high-profile nanotech program developed by Dr. Joseph Simone and Liquidia. In an exclusive interview with WRALTechWire, the lead author of a new paper describes the potentially big breakthrough using small, small particles.
The North Carolina Chamber will unveil an economic development "Dashboard" created by RTI International on Dec. 3 as part of its Vision 2030 project. Those involved may want to look at new demographic data compiled at UNC which projects where most people in the state will be living in 2050. Are you ready for a Charlotte-Triad-Triangle megalopolis?
Plenty of tech and biotech companies have been founded at the University of North Carolina at Chapel Hill but the university has also proved to be a fertile breeding ground for entrepreneurship in public health. Read about four public health spinouts from UNC's Gillings School of Public Health.
When 100 of the top lung doctors in the U.S. gathered in Houston recently to learn about GlaxoSmithKline's new respiratory drug, one message rang loud and clear: Don't ignore the pneumonia risk. It's part of a new "Patient First" strategy from GSK.
The Certified Educational Chief Technology Officer (CeCTO) program finished its fourth cohort and welcomed 20 new CeCTOs and 11 Leaders of the 21st Century last week in Chapel Hill.
Two University of North Carolina scientists are among the winners in a GSKcompetition designed to find potential new drugs in places other than pharmaceutical company labs. Read about what this means for the scientists and for GSK.
Joseph DeSimone, whose nanotechnology research in University of North Carolina at Chapel Hill labs formed the basis for spinout Liquidia Technologies, will step down as director of UNC's Kenan Institute of Private Enterprise 18 months after taking the top position.
Cree reports revenues of $391 million and earnings of 39 cents per share, both figures topping Wall Street analysts' expectations by a considerable margin. However, investors expected higher numbers for the current quarter. Shares opened sharply lower Wednesday, and two analysts cut their ratings on the stock.
OxyBio shares close up 30% after trifecta: Acquires pharma firm, hires CEO, adds potential $600M drug
Wall Street likes this deal. Morrisville-based OxyBio says it is buying privately held Phyxius Pharma for some $4.8 million in stock and is naming the co-founder and CEO of that company as its chief executive officer. It's also acquiring the rights to a drug that could be worth $600 million a year.
The National Institutes of Health awards UNC-CH a five-year grant for programs, drug development and technology targeting the improvement of healthcare across North Carolina. RTI International and N.C. A&T will share in the contract. Duke, meanwhile, receives a $47 million grant.
In an effort to cut costs, reduce the number of re-admissions and improve quality of life for patients, the UNC Health Care system is going to utilize analytics from IBM.